Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches

45:42
 
Share
 

Manage episode 502594407 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Sarah Sammons, including the following topics:

  • Development of brain metastases in patients with HER2-positive and HER2-negative breast cancer (0:00)
  • Local therapy approaches for the treatment of brain metastases (8:23)
  • Treatment options for patients with HER2-positive breast cancer and CNS-only disease progression (16:36)
  • Clinical presentation of leptomeningeal disease; management of functional sequelae associated with brain metastases (19:07)
  • Investigational agents for the treatment of brain metastases in HER2-positive breast cancer (25:01)
  • Case: A 65-year-old woman with ER-negative, HER2-positive metastatic breast cancer (mBC) develops a single 6-mm brain metastasis after 4 years of maintenance trastuzumab/pertuzumab (27:38)
  • Screening for brain metastases; radiation necrosis as a side effect of radiation therapy (31:00)
  • Case: A 39-year-old woman with ER-negative, HER2-positive mBC develops 7 new brain metastases 6 months into treatment with a taxane, trastuzumab and pertuzumab (34:30)

CME information and select publications

  continue reading

740 episodes

Artwork
iconShare
 
Manage episode 502594407 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Featuring an interview with Dr Sarah Sammons, including the following topics:

  • Development of brain metastases in patients with HER2-positive and HER2-negative breast cancer (0:00)
  • Local therapy approaches for the treatment of brain metastases (8:23)
  • Treatment options for patients with HER2-positive breast cancer and CNS-only disease progression (16:36)
  • Clinical presentation of leptomeningeal disease; management of functional sequelae associated with brain metastases (19:07)
  • Investigational agents for the treatment of brain metastases in HER2-positive breast cancer (25:01)
  • Case: A 65-year-old woman with ER-negative, HER2-positive metastatic breast cancer (mBC) develops a single 6-mm brain metastasis after 4 years of maintenance trastuzumab/pertuzumab (27:38)
  • Screening for brain metastases; radiation necrosis as a side effect of radiation therapy (31:00)
  • Case: A 39-year-old woman with ER-negative, HER2-positive mBC develops 7 new brain metastases 6 months into treatment with a taxane, trastuzumab and pertuzumab (34:30)

CME information and select publications

  continue reading

740 episodes

Усі епізоди

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play